Life Sciences & Biotechnology

Life Science and biotechnology companies have set up shop in Singapore to service patients from all over the world and connect with the booming Asian market, thanks to the city-large state's pool of trained manpower, robust manufacturing capabilities, and dynamic research ecosystem.

Companies in the life sciences and biomedical fields are expanding their presence in Asia, particularly in Singapore, where development is expected to be steady. Increased spending on general public health care, expanding prospective patient pools, and bolstering consumer demand are all part of the expansion strategy. Sales offices, manufacturing operations, and research and development (R&D) facilities are all expanding throughout Asia as a result of these gains.

 

Singapore maintains its commitment to developing a personnel base capable of meeting future manufacturing demands. The pharmaceutical and biotechnology production sector in Singapore is currently backed by about 4,800 experienced engineers and technicians, according to the Economic Development Board Singapore.

Changes in the life sciences sector

Globally, ageing populations and chronic diseases like Covid-19 are exerting strain on health resources, while scientific advancements, augmented intelligence, and digital data are altering traditional health-care approaches. This has resulted in a power shift, with fresh entrants (often not motivated by profit) upsetting the incumbents.

 

  • The workplace, and the workforce are being redesigned while individual needs are being met : Workplaces are being redesigned from virtual workspaces to new sorts of off-site cooperation as more life sciences organizations work from remote locations. Companies in the life sciences sector are increasingly focused on their employees’ particular requirements and fostering well-being. This increase in connectedness, as well as the blurring of geographical borders, is broadening the pool of talent and increasing access to skills.
  • Digitization at a faster pace : In the life sciences industry, digitization has resulted in more new point-of-care systems, digital pharmacy installations, and quick and efficient access to health care. Virtual care can fundamentally change health care access and provide a better care experience with the use of digital health solutions.
  • R&D is being reshaped by new sorts of cooperation and clinical trials : To improve efficiencies, businesses are re-evaluating and questioning their existing practices. They’re also looking for new ways to collaborate in order to succeed. Additionally, with telemedicine and mobile health care, organizations are turning toward virtual trials and remote monitoring in order to include more patients in their research.

What Bluebox can do?

By developing the proper alliances, better allocating resources, and building trust with consumers, we assist firms in the biotechnology, pharmaceutical, and medical technology areas leverage this disruption. We look at how COVID-19 drove change in the sector, what changes are likely to stick around, and what can be re-invented and improved. It also examines several scenarios for stakeholders to see how these adjustments can improve the sector’s transformation.
Scroll to Top